Metagenomi Reports Third Quarter 2025 Financial Results and Announces Strategic Pipeline Prioritization and Leadership Updates

Core Insights - Metagenomi, Inc. is advancing its MGX-001 hemophilia A program into clinical development following promising preclinical results demonstrating curative FVIII activity in non-human primates [1][4] - The company has undergone an organizational restructuring, reducing its workforce by 25% to optimize resources and extend its cash runway into the fourth quarter of 2027 [1][3] - Jian Irish, Ph.D., M.B.A., has been appointed as the new Chief Executive Officer, succeeding Brian Thomas, who will remain on the Board of Directors [1][2] Financial Performance - As of September 30, 2025, the company reported cash, cash equivalents, and available-for-sale marketable securities totaling $184.1 million, expected to support operations until the fourth quarter of 2027 [7] - Research and development expenses for the third quarter of 2025 were $25.3 million, a decrease from $26.3 million in the same period of 2024 [7] - General and administrative expenses were reported at $6.2 million for the third quarter of 2025, down from $7.6 million in the comparable period in 2024 [8] Strategic Focus - The company is prioritizing its MGX-001 hemophilia A program and other secreted protein deficiencies while deprioritizing early discovery and platform research [11][12] - Metagenomi aims to leverage its advanced gene-editing technologies to address unmet medical needs and create near-term value [3][12] - The company is also pursuing cardiometabolic indications in collaboration with Ionis, indicating a strategic expansion of its therapeutic pipeline [11][12] Upcoming Milestones - A pre-IND meeting for MGX-001 is anticipated in the fourth quarter of 2025, with IND/CTA submissions expected in the fourth quarter of 2026 [1] - The company is on track to achieve proof-of-concept data for its lead secreted protein deficiency target in 2025 [5]